Olsen GM, Hansen LM, Stefanko NS, et al. - This multicenter retrospective cohort study was designed to evaluate the incidence of adverse events among patients with PHACE syndrome receiving oral propranolol for infantile hemangioma. The incidence of adverse events was investigated among 76 individuals with PHACE syndrome receiving oral propranolol for infantile hemangioma at 11 tertiary care, academic pediatric dermatology practices. Researchers examined medical records between January 1, 2010, and April 25, 2017. This study recruited a sum of 76 individuals (59 girls and 17 boys; median age at propranolol initiation, 56 days [range, 0-396 days]). In 76 individuals with PHACE syndrome, it was indicated that oral propranolol was applied to treat infantile hemangioma and that no serious adverse events were experienced. In this patient population, these data give support for the safety of oral propranolol.